News

Categories

April 30, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

April 11, 2024

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

April 8, 2024

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

April 2, 2024

Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed

March 28, 2024

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

March 27, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

March 6, 2024

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

March 5, 2024

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

February 27, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

February 14, 2024

Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call

February 8, 2024

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

January 31, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences